MARKET

ABBV

ABBV

Abbvie Inc
NYSE
171.36
+1.68
+0.99%
After Hours: 171.36 0 0.00% 19:50 06/18 EDT
OPEN
170.44
PREV CLOSE
169.68
HIGH
173.01
LOW
169.87
VOLUME
4.25M
TURNOVER
0
52 WEEK HIGH
182.89
52 WEEK LOW
125.85
MARKET CAP
302.60B
P/E (TTM)
51.04
1D
5D
1M
3M
1Y
5Y
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
NASDAQ · 4h ago
My Dividend Stock Portfolio: New May Dividend Record - 101 Holdings With 22 Buys
Stefan Redlich's dividend income hit an all-time high in May, up 13% Y/Y and 136% sequentially. In May, he added $149 to his yearly dividend income. His portfolio now has 101 Holdings with 22 Buys. Main portfolio picks included Ares Capital, Hercules Capital and Goldman Sachs BDC.
Seeking Alpha · 4h ago
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
AbbVie is the maker of the blockbuster drug Humira. Starbucks faces challenges, but the company is a great long-term investment. The company's dividend yield is near its highest point in 10 years. Abbvie has raised its dividend annually since it became a public company.
The Motley Fool · 8h ago
AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis
NASDAQ · 11h ago
AbbVie says FDA approves Skyrizi for ulcerative colitis
MarketWatch · 18h ago
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis
Dow Jones · 18h ago
AbbVie: 5 Reasons That Make A Buy Case
Seeking Alpha · 19h ago
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
NASDAQ · 1d ago
More
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.